ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Following validation of hits, we focused on Ponatinib, which is an FDA-approved kinase inhibitor for chronic myeloid leukemia (CML) targeting BCR-ABL-T315I mutant32,33.